CA
NZ
UK
AU
IND
US
…
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aprea Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies and advancing drug candidates through clinical trials. Major long-term growth drivers include successful late-stage trial readouts, regulatory approvals for oncology indications, and strategic collaborations that could support commercialization; investors may find the company attractive because it appears positioned to benefit from unmet needs in specific cancer subtypes if clinical programs demonstrate efficacy.
Material risks include high clinical and regulatory risk, dependence on trial outcomes and partners, potential for capital raises and dilution, and limited revenues until regulatory approval.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Net income | -12.60M | -12.96M | -14.29M | -224.88M | -36.54M |
| Selling general administrative | 6.48M | 6.46M | 8.43M | 20.97M | 13.55M |
| Selling and marketing expenses | - | - | 0.01M | - | - |
| Gross profit | 0.26M | -7.86M | 0.58M | - | - |
| Reconciled depreciation | 0.02M | 0.02M | -0.00M | 0.19M | 0.27M |
| Ebit | -13.26M | -14.32M | -14.29M | 38.18M | -38.04M |
| Ebitda | -13.23M | -14.30M | -14.28M | 38.37M | -37.76M |
| Depreciation and amortization | 0.02M | 0.02M | 0.01M | 0.19M | 0.27M |
| Operating income | -13.23M | -14.32M | -15.47M | 38.18M | -38.04M |
| Other operating expenses | 13.52M | 15.82M | 16.06M | 37.37M | 37.45M |
| Interest expense | - | - | - | 0.45M | 0.00M |
| Interest income | 0.65M | 1.29M | 1.22M | 0.45M | 0.00M |
| Net interest income | 0.65M | 1.29M | 1.16M | 0.45M | 0.00M |
| Income tax expense | - | - | -0.00M | 112.21M | -0.59M |
| Total revenue | 0.29M | 1.50M | 0.58M | 0.00M | 0.00M |
| Total operating expenses | 13.52M | 6.46M | 16.05M | 37.37M | 37.45M |
| Cost of revenue | 0.02M | 9.36M | 0.01M | - | - |
| Total other income expense net | 0.63M | 1.36M | 1.19M | -150.84M | 0.91M |
| Net income from continuing ops | -12.60M | -12.96M | -13.29M | -112.66M | -37.13M |
| Net income applicable to common shares | - | - | - | -112.66M | -37.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Other current assets | 0.96M | 0.73M | 0.91M | 1.37M | 3.51M |
| Total liab | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Total stockholder equity | 13.17M | 19.31M | 18.26M | 25.64M | 49.51M |
| Other current liab | 2.05M | 2.01M | 2.19M | 2.36M | 5.35M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.02M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.02M |
| Retained earnings | -333.64M | -321.04M | -308.08M | -293.80M | -181.13M |
| Other assets | - | - | - | - | 0.03M |
| Cash | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total current liabilities | 2.76M | 3.36M | 4.39M | 3.20M | 7.32M |
| Current deferred revenue | - | - | 0.53M | - | - |
| Net debt | -14.60M | -22.85M | -21.61M | -28.79M | -52.89M |
| Short term debt | - | - | - | - | 0.19M |
| Short long term debt total | - | - | - | - | 0.19M |
| Other stockholder equity | 356.71M | 350.97M | 335.64M | 328.75M | 240.98M |
| Property plant equipment | - | - | - | 0.00M | 0.21M |
| Total current assets | 15.56M | 23.58M | 22.52M | 30.15M | 56.58M |
| Net tangible assets | - | - | - | 25.64M | 49.51M |
| Accounts payable | 0.71M | 1.35M | 1.67M | 0.84M | 1.77M |
| Accumulated other comprehensive income | -10.63M | -10.63M | -10.61M | -10.62M | -10.36M |
| Non currrent assets other | 0.27M | 0.28M | 0.04M | - | 0.03M |
| Non current assets total | 0.37M | 0.40M | 0.13M | 0.00M | 0.24M |
| Capital lease obligations | - | - | - | 0.00M | 0.19M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.02M | -0.09M | 0.00M | 0.00M |
| Change to liabilities | - | - | - | -0.86M | -2.73M |
| Total cashflows from investing activities | - | -0.02M | -0.09M | - | - |
| Total cash from financing activities | 4.64M | 14.82M | 5.14M | 0.68M | 1.75M |
| Change to operating activities | - | - | - | -0.90M | -5.60M |
| Net income | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Change in cash | -8.25M | 1.24M | -7.14M | -24.29M | -35.94M |
| Begin period cash flow | 22.89M | 21.65M | 28.79M | 53.08M | 89.02M |
| End period cash flow | 14.64M | 22.89M | 21.65M | 28.79M | 53.08M |
| Total cash from operating activities | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Issuance of capital stock | 5.05M | 16.14M | 5.89M | 0.68M | 1.54M |
| Depreciation | 0.02M | 0.02M | 0.01M | 0.19M | 0.27M |
| Other cashflows from financing activities | 4.64M | -1.32M | -0.65M | -69.42M | 0.21M |
| Change to netincome | - | - | - | 89.22M | 7.50M |
| Capital expenditures | 0.00M | 0.02M | 0.09M | 0.00M | 0.00M |
| Change in working capital | -0.93M | -1.06M | 1.62M | -1.76M | -8.33M |
| Stock based compensation | 0.48M | 0.49M | 0.44M | 16.98M | 7.81M |
| Other non cash items | 0.13M | -0.05M | 0.04M | 72.24M | -0.32M |
| Free cash flow | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| APRE Aprea Therapeutics Inc |
-0.01 1.82% |
0.48 | - | - | 1838.28 | 0.26 | 0.35 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christian S. Schade | Chairman & CEO | 1961 |
| Dr. Oren Gilad Ph.D. | Co-Founder, Pres & Director | 1968 |
| Mr. Scott M. Coiante | Sr. VP, CFO & Sec. | 1967 |
| Dr. Gregory A. Korbel Ph.D. | Sr. VP & COO | 1976 |
| Dr. Dansu Li Ph.D. | Head of Technology | NA |
| Dr. Lars B. Abrahmsen Ph.D. | Sr. VP & Chief Scientific Officer | 1957 |
| Dr. Rifat Pamukcu M.D. | Chief Medical Advisor & Director | 1958 |
| Mr. Hank Breslin | Head of Medicinal Chemistry | NA |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Devel. | NA |
| Ms. Andrea Epstein | Controller | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...